The In-Vitro Diagnostic (IVD) Substances market in the US demonstrated a steady upward trend from 2013 to 2023, growing from $11.978 billion to $12.92 billion. This growth represents around a 1.1% year-on-year increase in 2023, continuing a general trend of incremental rises reflected by an average annual growth rate (CAGR) of 1.17% over the past five years. Through 2028, it is anticipated that the market will sustain its growth trajectory, albeit at a slower pace, with a forecasted 5-year CAGR of 0.79% and a forecasted growth rate of 4%.

Future Trends to Watch For:

• Rising demand for more accurate and early diagnostic tests as healthcare prioritizes preventive measures
• Increased adoption of personalized medicine, necessitating specialized diagnostic substances
• Technological advancements in molecular diagnostics and point-of-care testing
• Regulatory changes and their impacts on market dynamics
• Expansion in developing markets, potentially influencing global market dynamics